PL3442557T3 - Lek do skutecznej kontroli ostrego i/lub przewlekłego bólu oraz sposób jego podawania - Google Patents

Lek do skutecznej kontroli ostrego i/lub przewlekłego bólu oraz sposób jego podawania

Info

Publication number
PL3442557T3
PL3442557T3 PL17782756.5T PL17782756T PL3442557T3 PL 3442557 T3 PL3442557 T3 PL 3442557T3 PL 17782756 T PL17782756 T PL 17782756T PL 3442557 T3 PL3442557 T3 PL 3442557T3
Authority
PL
Poland
Prior art keywords
acute
chronic pain
effective control
drug formulation
formulation
Prior art date
Application number
PL17782756.5T
Other languages
English (en)
Inventor
Vyacheslav Stanislavovich KOSORUKOV
Evgeny Stanislavovich RZHANINOV
Nikolai Vasilievich Korobov
Original Assignee
Pvp Labs Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10201602973WA external-priority patent/SG10201602973WA/en
Priority claimed from RU2016133329A external-priority patent/RU2622980C3/ru
Application filed by Pvp Labs Pte. Ltd. filed Critical Pvp Labs Pte. Ltd.
Publication of PL3442557T3 publication Critical patent/PL3442557T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17782756.5T 2016-04-14 2017-04-13 Lek do skutecznej kontroli ostrego i/lub przewlekłego bólu oraz sposób jego podawania PL3442557T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201602973WA SG10201602973WA (en) 2016-04-14 2016-04-14 Method of development of an analgesic peptide preparation, for the treatment of acute and chronic pain
RU2016133329A RU2622980C3 (ru) 2016-08-12 Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения
PCT/SG2017/050210 WO2017180064A1 (en) 2016-04-14 2017-04-13 A drug for the effective control of acute and/or chronic pain and a method for its administration

Publications (1)

Publication Number Publication Date
PL3442557T3 true PL3442557T3 (pl) 2023-01-09

Family

ID=60042549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17782756.5T PL3442557T3 (pl) 2016-04-14 2017-04-13 Lek do skutecznej kontroli ostrego i/lub przewlekłego bólu oraz sposób jego podawania

Country Status (15)

Country Link
US (1) US10357533B2 (pl)
EP (1) EP3442557B1 (pl)
CN (1) CN108697758B (pl)
CA (1) CA3056222C (pl)
DK (1) DK3442557T3 (pl)
ES (1) ES2930757T3 (pl)
FI (1) FI3442557T3 (pl)
HR (1) HRP20221395T1 (pl)
HU (1) HUE060669T2 (pl)
LT (1) LT3442557T (pl)
PL (1) PL3442557T3 (pl)
PT (1) PT3442557T (pl)
RS (1) RS63779B1 (pl)
SI (1) SI3442557T1 (pl)
WO (1) WO2017180064A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210205404A1 (en) * 2018-05-16 2021-07-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition of kor receptor agonist
US20240239840A1 (en) * 2023-01-18 2024-07-18 Pvp Labs Pte.Ltd. method for the treatment of pain and a medicinal product for administration during pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58213743A (ja) 1982-06-07 1983-12-12 Dai Ichi Seiyaku Co Ltd テトラペプチド誘導体
JPS6054400B2 (ja) 1982-12-27 1985-11-29 黒沢通信工業株式会社 めつき装置
JPS6054400A (ja) 1983-09-01 1985-03-28 Grelan Pharmaceut Co Ltd テトラペプチド
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
RU2538727C1 (ru) 2013-11-15 2015-01-10 Закрытое акционерное общество "Институт экспериментальной фармакологии" Анальгетическое средство пептидной структуры на основе тридекапептида, содержащего d-октааргининовый вектор

Also Published As

Publication number Publication date
CN108697758A (zh) 2018-10-23
HRP20221395T1 (hr) 2023-01-06
LT3442557T (lt) 2022-12-12
EP3442557B1 (en) 2022-10-05
PT3442557T (pt) 2022-11-23
HUE060669T2 (hu) 2023-04-28
US20180221432A1 (en) 2018-08-09
SI3442557T1 (sl) 2023-01-31
CA3056222A1 (en) 2017-10-19
WO2017180064A1 (en) 2017-10-19
CA3056222C (en) 2020-09-29
CN108697758B (zh) 2022-12-02
FI3442557T3 (fi) 2022-12-15
DK3442557T3 (da) 2022-11-28
EP3442557A1 (en) 2019-02-20
ES2930757T3 (es) 2022-12-21
RS63779B1 (sr) 2022-12-30
EP3442557A4 (en) 2019-12-25
US10357533B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
IL274162A (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
SG11202003320SA (en) Dihydropyrimidine compounds and uses thereof in medicine
PL3256218T3 (pl) Inhibitor kdm1a i jego zastosowanie w terapii
ZA201904653B (en) Compositions and methods for the treatment of chronic pain
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
GB201715194D0 (en) Compounds and their therapeutic use
GB201604213D0 (en) Drug combination and its use in therapy
ZA201705561B (en) Kv1.3 inhibitors and their medical application
SG11201801981UA (en) Therapeutic substance delivery device and therapeutic substance delivery kit
GB201617064D0 (en) Compounds and their therapeutic use
GB201711190D0 (en) Use of cannabininoids in the treatment of a neurodegenerative disease or disorder
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
IL273863B1 (en) Hemorrhoid treatment device
PT3423042T (pt) Formulação farmacêutica liofilizada e sua utilização
HUE060669T2 (hu) Gyógyszerforma akut és/vagy krónikus fájdalom hatásos csökkentésében történõ alkalmazásra
PT3325478T (pt) Novo composto terapêutico e a utilização em terapia
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
PL3630188T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
ZA201705676B (en) Kv1.3 inhibitors and their medical application
GB201519644D0 (en) Therapy and pharmaceutical composition
PT3177283T (pt) Composto ativo e composição relacionada pata utilização dermatológica no campo farmacêutico ou cosmético
GB201802743D0 (en) Medicament and use thereof
GB201718320D0 (en) Therapeutic substances and their preparation